

## Personal Information

**Email:** zehraozsoy@hacettepe.edu.tr

**Web:** <https://avesis.hacettepe.edu.tr/zehraozsoy>

## Research Areas

Medicine, Internal Medicine Sciences, Health Sciences

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Apical fibrobullous lung disease in spondyloarthritis patients with biologic DMARDs indication**  
ÖZSOY Z., AYAN G., DURHAN G., KALYONCU U.  
Rheumatology (United Kingdom), vol.63, no.4, pp.1147-1152, 2024 (SCI-Expanded)
- II. **Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)**  
BİLGİN E., Demirci Yıldırım T., Özdemir Ulusoy B., Ögüt T. S., Karabacak M., Sadioğlu Çağdaş Ö., YILDIRIM R., Güven D. C., Akleylek C., Ediboğlu E., et al.  
Internal and Emergency Medicine, 2024 (SCI-Expanded)
- III. **Factors that predict development of chronic kidney disease in patients with rheumatoid arthritis receiving biologic DMARDs and mortality rates**  
Sandal Uzun G., Taghiyeva A., Çakır İ. Y., Moral K., YARDIMCI G. K., Bölek E. Ç., Farisoğulları B., Duran E., AYAN G., ÖZSOY Z., et al.  
International Journal of Rheumatic Diseases, vol.27, no.1, 2024 (SCI-Expanded)
- IV. **Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?**  
ÖZSOY Z., ÖZDEMİR A., EKİCİ M., BİLGİN E., KILIÇ L., KIRAZ S., SARIBAŞ Z., ŞENER B., KARADAĞ Ö.  
Rheumatology International, vol.43, no.8, pp.1445-1451, 2023 (SCI-Expanded)
- V. **Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry**  
Duran E., Ozturk Z. O., BİLGİN E., BÜYÜKAŞIK Y., DİZDAR Ö., Yardimci G. K., Farisogullari B., ÖZSOY Z., AYAN G., Uzun G. S., et al.  
Rheumatology and Therapy, vol.10, no.4, pp.969-981, 2023 (SCI-Expanded)
- VI. **Comparison of demographic, clinic and radiological features of patients with axial spondyloarthritis accompanying familial Mediterranean fever to patients with each condition alone**  
Kiracı M., BİLGİN E., Duran E., Farisoğulları B., Bölek E., Yardımcı G., ÖZSOY Z., AYAN G., UZUN G., AKBABA T. H., et al.  
Scandinavian Journal of Rheumatology, vol.52, no.5, pp.530-538, 2023 (SCI-Expanded)
- VII. **Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results**  
AYAN G., Farisogullari B., BİLGİN E., BÖLEK E. Ç., KubraYardimci G., DURAN E., ÖZSOY Z., Uzun G. S., KILIÇ L., AKDOĞAN A., et al.  
CLINICAL RHEUMATOLOGY, vol.41, no.5, pp.1439-1446, 2022 (SCI-Expanded)
- VIII. **Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis**

Bostan E., GÜLSEREN D., ÖZSOY Z., Ergen F. B.

Archives of Rheumatology, vol.37, no.1, pp.148-149, 2022 (SCI-Expanded)

**IX. Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever**

Kiraci M., BİLGİN E., Duran E., Farisogullari B., Bolek E. C., YARDIMCI G. K., ÖZSOY Z., AYAN G., Uzun G. S., AKBABA T. H., et al.

ARTHRITIS & RHEUMATOLOGY, vol.73, pp.771-773, 2021 (SCI-Expanded)

## **Metrics**

Publication: 9

Citation (Scopus): 2

H-Index (Scopus): 1